Tech Company Financing Transactions
RetroSense Therapeutics Funding Round
RetroSense Therapeutics, based in Ann Arbor, secured $6 million in investment from Blue Water Capital, Michigan Economic Development Corporation and Nerveda.
Transaction Overview
Company Name
Announced On
1/10/2015
Transaction Type
Venture Equity
Amount
$6,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to enable completion of preclinical studies needed to support an Investigational New Drug (IND) filing with the U.S. Food and Drug Administration for its lead compound, RST-001 for the treatment of Retinitis Pigmentosa, a cause of vision loss and blindness.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
330 East Liberty Street LL
Ann Arbor, MI 48104
USA
Ann Arbor, MI 48104
USA
Phone
Website
Email Address
Overview
Led by a team of seasoned veterans, RetroSense Therapeutics was founded in 2009 to develop a novel gene therapy approach to vision restoration.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sean Ainsworth
Chief Medical Officer
Peter Francis
Chief Operating Officer
Thomas Rea
Browse more venture capital transactions:
Prev: 1/9/2015: Reset Therapeutics venture capital transaction
Next: 1/10/2015: Okanjo venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We report on every notable VC transaction. All VC database entries reported here are derived from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs